ImaginAb's Biotech Platform Acquired by Telix for Innovative Therapeutic Discovery

Deal News | Jan 23, 2025 | PR Newswire Cision ImaginAb, Inc.

ImaginAb, a clinical-stage biotechnology company, announced the sale of its innovative therapeutic candidates platform to Telix Pharmaceuticals. This transaction will allow ImaginAb to focus on its imaging product, CD8 ImmunoPET, in clinical trials. ImaginAb also plans to continue developing its prostate cancer imaging agent. Financial advisors Jefferies LLC and Stifel, Nicolaus & Company assisted ImaginAb in this transaction. The sale confirms the potential of ImaginAb's technology. Telix plans to utilize the acquired technology for radiotherapeutic advancements. ImaginAb, backed by major venture capital and strategic companies, continues its active involvement in innovating next-generation radiopharmaceuticals.

Sectors

  • Biotechnology
  • Pharmaceuticals

Geography

  • United States – ImaginAb is a U.S.-based biotechnology firm, headquartered in Inglewood, California.
  • Australia – Telix Pharmaceuticals is an Australian company listed on the ASX.

Industry

  • Biotechnology – The article involves ImaginAb, a biotechnology firm focused on radiopharmaceuticals and imaging agents.
  • Pharmaceuticals – Telix Pharmaceuticals is acquiring a biotech platform, indicating its position in the pharmaceutical industry.

Financials

    Participants

    NameRoleTypeDescription
    ImaginAb, Inc.Target CompanyCompaniesA clinical-stage biotechnology company focusing on the development of radiopharmaceuticals and imaging products.
    Telix Pharmaceuticals LimitedBidding Company/BuyerCompaniesAn Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products.
    Jefferies LLCFinancial AdvisorCompaniesProvided financial advisory services to ImaginAb in the transaction.
    Stifel, Nicolaus & Company, IncorporatedFinancial AdvisorCompaniesProvided financial advisory services to ImaginAb in the transaction.
    Dre Anna WuFounder of ImaginAbPeopleFounder of ImaginAb and spokesperson in the article.
    Adage Capital, The Cycad Group, Norgine Ventures, Innoviva, Jim Pallotta, Raptor Group, The Parker Institute for Cancer Immunotherapy, Merck (MSD) PharmaInvestorsCompaniesKey investors and supporters of ImaginAb.